Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $1,460,000 | $1,391,600 | $808,700 | $917,700 |
| Dep. & Amort. | $136,700 | $135,100 | $126,900 | $126,400 |
| Deferred Tax | -$278,600 | -$135,200 | -$139,100 | -$280,200 |
| Stock-Based Comp. | $237,000 | $251,700 | $255,700 | $304,400 |
| Change in WC | $98,300 | -$227,900 | $129,600 | -$86,400 |
| Other Non-Cash | -$34,700 | -$270,900 | -$136,700 | $280,900 |
| Operating Cash Flow | $1,618,700 | $1,144,400 | $1,045,100 | $1,262,800 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$201,400 | -$219,000 | -$229,300 | -$267,000 |
| Net Acquisitions | -$3,000 | $0 | $0 | -$11,500 |
| Inv. Purchases | -$3,520,200 | -$2,855,100 | -$2,539,300 | -$1,952,900 |
| Inv. Sales/Matur. | $3,365,000 | $2,167,900 | $3,458,300 | $2,582,000 |
| Other Inv. Act. | -$43,300 | -$187,800 | -$42,200 | $0 |
| Investing Cash Flow | -$402,900 | -$1,094,000 | $647,500 | $350,600 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $40,300 | $31,500 | $60,600 | $90,900 |
| Stock Repurch. | -$659,700 | -$1,061,500 | -$1,045,700 | -$1,226,400 |
| Dividends Paid | -$91,200 | -$92,600 | -$93,800 | $0 |
| Other Fin. Act. | -$7,300 | -$5,600 | -$10,300 | $0 |
| Financing Cash Flow | -$717,900 | -$1,128,200 | -$1,089,200 | -$1,135,500 |
| Forex Effect | -$400 | $400 | $600 | -$700 |
| Net Chg. in Cash | $497,500 | -$1,077,400 | $604,000 | $477,200 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $2,015,600 | $3,093,000 | $2,489,000 | $2,011,800 |
| End Cash | $2,513,100 | $2,015,600 | $3,093,000 | $2,489,000 |
| Free Cash Flow | $1,417,300 | $967,600 | $773,600 | $995,800 |